Wall Street analysts forecast that Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) will report earnings per share of ($1.58) for the current quarter, according to Zacks Investment Research. Seven analysts have made estimates for Ultragenyx Pharmaceutical’s earnings, with the highest EPS estimate coming in at ($1.31) and the lowest estimate coming in at ($1.85). Ultragenyx Pharmaceutical reported earnings per share of ($1.72) in the same quarter last year, which would suggest a positive year-over-year growth rate of 8.1%. The business is scheduled to report its next earnings report on Thursday, August 6th.
On average, analysts expect that Ultragenyx Pharmaceutical will report full-year earnings of ($6.46) per share for the current fiscal year, with EPS estimates ranging from ($7.46) to ($4.81). For the next fiscal year, analysts expect that the company will report earnings of ($4.53) per share, with EPS estimates ranging from ($6.06) to ($0.13). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.68) by ($0.23). Ultragenyx Pharmaceutical had a negative net margin of 348.78% and a negative return on equity of 60.65%. The firm had revenue of $36.31 million for the quarter, compared to analyst estimates of $36.74 million. During the same quarter last year, the business posted ($1.82) earnings per share. The firm’s revenue for the quarter was up 99.8% compared to the same quarter last year.
Several brokerages have recently issued reports on RARE. Credit Suisse Group lifted their price target on Ultragenyx Pharmaceutical from $60.00 to $64.00 and gave the company a “neutral” rating in a research report on Wednesday. Wedbush lifted their price target on Ultragenyx Pharmaceutical from $83.00 to $91.00 and gave the company an “outperform” rating in a research report on Wednesday. Morgan Stanley lifted their price target on Ultragenyx Pharmaceutical from $79.00 to $83.00 and gave the company an “overweight” rating in a research report on Wednesday. Canaccord Genuity lifted their price target on Ultragenyx Pharmaceutical from $85.00 to $91.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Piper Sandler lifted their target price on Ultragenyx Pharmaceutical from $70.00 to $83.00 and gave the stock an “overweight” rating in a report on Tuesday. Four equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $80.00.
Shares of RARE stock traded up $1.39 during mid-day trading on Monday, hitting $86.04. 665,237 shares of the stock traded hands, compared to its average volume of 626,550. Ultragenyx Pharmaceutical has a twelve month low of $31.99 and a twelve month high of $86.11. The firm has a market cap of $5.13 billion, a price-to-earnings ratio of -11.71 and a beta of 2.28. The company’s 50-day simple moving average is $72.53 and its 200-day simple moving average is $57.90. The company has a debt-to-equity ratio of 0.06, a quick ratio of 4.49 and a current ratio of 4.54.
In other news, Director Matthew K. Fust sold 1,875 shares of the firm’s stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $65.00, for a total value of $121,875.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Theodore Alan Huizenga sold 2,461 shares of the firm’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $71.00, for a total value of $174,731.00. Following the completion of the sale, the senior vice president now directly owns 18,719 shares of the company’s stock, valued at approximately $1,329,049. The disclosure for this sale can be found here. In the last ninety days, insiders sold 26,555 shares of company stock valued at $1,942,395. 8.20% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Capital Research Global Investors lifted its position in shares of Ultragenyx Pharmaceutical by 3.3% in the first quarter. Capital Research Global Investors now owns 6,573,960 shares of the biopharmaceutical company’s stock worth $292,081,000 after buying an additional 211,265 shares during the last quarter. Capital International Investors lifted its holdings in Ultragenyx Pharmaceutical by 1.5% during the 1st quarter. Capital International Investors now owns 6,132,194 shares of the biopharmaceutical company’s stock worth $272,453,000 after buying an additional 89,619 shares in the last quarter. Federated Hermes Inc. lifted its holdings in Ultragenyx Pharmaceutical by 35.2% during the 1st quarter. Federated Hermes Inc. now owns 4,016,760 shares of the biopharmaceutical company’s stock worth $178,465,000 after buying an additional 1,044,752 shares in the last quarter. Capital World Investors raised its position in shares of Ultragenyx Pharmaceutical by 36.5% during the 4th quarter. Capital World Investors now owns 3,237,295 shares of the biopharmaceutical company’s stock valued at $138,265,000 after acquiring an additional 865,865 shares during the last quarter. Finally, State Street Corp raised its position in shares of Ultragenyx Pharmaceutical by 1.4% during the 1st quarter. State Street Corp now owns 2,229,351 shares of the biopharmaceutical company’s stock valued at $99,050,000 after acquiring an additional 30,604 shares during the last quarter. 99.91% of the stock is owned by hedge funds and other institutional investors.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.
Featured Article: Profit margin is different from the revenue
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.